IL212589A - Link proteins that inhibit the a-vegf receptor - Google Patents
Link proteins that inhibit the a-vegf receptorInfo
- Publication number
- IL212589A IL212589A IL212589A IL21258911A IL212589A IL 212589 A IL212589 A IL 212589A IL 212589 A IL212589 A IL 212589A IL 21258911 A IL21258911 A IL 21258911A IL 212589 A IL212589 A IL 212589A
- Authority
- IL
- Israel
- Prior art keywords
- vegf
- binding proteins
- receptor interaction
- proteins inhibiting
- inhibiting
- Prior art date
Links
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 230000010799 Receptor Interactions Effects 0.000 title 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 title 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 title 1
- 108091008324 binding proteins Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Ophthalmology & Optometry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08168166 | 2008-11-03 | ||
| PCT/EP2009/064483 WO2010060748A1 (en) | 2008-11-03 | 2009-11-03 | Binding proteins inhibiting the vegf-a receptor interaction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL212589A0 IL212589A0 (en) | 2011-07-31 |
| IL212589A true IL212589A (en) | 2017-01-31 |
Family
ID=40149742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL212589A IL212589A (en) | 2008-11-03 | 2011-04-28 | Link proteins that inhibit the a-vegf receptor |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8901076B2 (https=) |
| EP (2) | EP3785735A1 (https=) |
| JP (2) | JP5954990B2 (https=) |
| KR (1) | KR101698362B1 (https=) |
| CN (2) | CN107011425B (https=) |
| AU (1) | AU2009319204B2 (https=) |
| BR (1) | BRPI0921469B1 (https=) |
| CA (1) | CA2742241C (https=) |
| DK (1) | DK2358746T3 (https=) |
| ES (1) | ES2836948T3 (https=) |
| IL (1) | IL212589A (https=) |
| MX (2) | MX2011004649A (https=) |
| NZ (1) | NZ592591A (https=) |
| RU (2) | RU2550258C2 (https=) |
| WO (1) | WO2010060748A1 (https=) |
Families Citing this family (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9829494B2 (en) | 2005-12-01 | 2017-11-28 | Adrenomed Ag | Methods of treatment using ADM antibodies |
| RU2494108C2 (ru) | 2006-04-07 | 2013-09-27 | Аерпио Терапетикс, Инк. | Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование |
| AU2014243418B2 (en) * | 2010-04-30 | 2016-09-22 | Molecular Partners Ag | Modified binding proteins inhibiting the VEGF-A receptor interaction |
| AR081361A1 (es) | 2010-04-30 | 2012-08-29 | Molecular Partners Ag | Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a |
| PL2643349T3 (pl) * | 2010-11-26 | 2020-03-31 | Molecular Partners Ag | Zaprojektowane białka z powtórzeniami wiążące się z albuminą surowicy |
| EA201391607A1 (ru) | 2011-04-29 | 2014-04-30 | Янссен Байотек, Инк. | Связывающие il4/il13 белки с повторами и их применение |
| WO2012172054A1 (en) | 2011-06-16 | 2012-12-20 | Scil Proteins Gmbh | Modified multimeric ubiquitin proteins binding vegf-a |
| WO2013056240A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
| IL283215B2 (en) | 2011-11-16 | 2024-05-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment and pharmaceutical compostions comprising the same |
| ES2494190T3 (es) | 2011-11-16 | 2014-09-15 | Adrenomed Ag | Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para reducir el riesgo de mortalidad en un paciente que padece una enfermedad crónica o aguda o un estado agudo |
| HRP20170427T1 (hr) | 2011-11-16 | 2017-06-16 | Sphingotec Gmbh | Testovi na adrenomedulin i postupci određivanja zrelog adrenomedulina |
| EP2780370B1 (en) | 2011-11-16 | 2019-09-25 | AdrenoMed AG | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
| LT3553084T (lt) | 2011-11-16 | 2023-03-10 | Adrenomed Ag | Anti-adrenomedulino (adm) antikūnas arba anti-adm antikūno fragmentas, arba anti-adm ne-ig karkasas, skirtas organų funkcijos sutrikimo arba organų nepakankamumo profilaktikai arba sumažinimui paciento, sergančio lėtine arba ūmine liga arba esančio ūminės būklės, organizme |
| PT2780371T (pt) | 2011-11-16 | 2019-01-30 | Adrenomed Ag | Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou uma estrutura não ig anti-adm para a regulação do equilíbrio de fluidos num doente com uma doença aguda ou crónica |
| CN103308673B (zh) | 2012-03-08 | 2017-05-31 | 思芬构技术有限公司 | 用于预测雌性对象中发生心血管事件的风险的方法 |
| CN103308670B (zh) | 2012-03-08 | 2017-06-09 | 思芬构技术有限公司 | 用于预测对象患糖尿病和/或代谢综合征的风险的方法 |
| CN103308689B (zh) | 2012-03-08 | 2017-04-12 | 思芬构技术有限公司 | 用于预测雌性对象中患上癌症的风险或诊断癌症的方法 |
| ES2753135T3 (es) * | 2012-05-07 | 2020-04-07 | Allergan Inc | Método de tratamiento de DMAE en pacientes resistentes a terapia anti-VEGF |
| PL3777834T3 (pl) | 2012-06-01 | 2022-05-30 | Novartis Ag | Strzykawka |
| WO2014001442A1 (en) * | 2012-06-28 | 2014-01-03 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| AU2012101677B4 (en) | 2012-07-03 | 2012-12-20 | Novartis Ag | Device |
| AU2013100070B4 (en) * | 2012-07-03 | 2013-04-04 | Novartis Ag | Use of device |
| DE202013000688U1 (de) | 2012-07-03 | 2013-03-05 | Novartis Ag | Glas-Spritze |
| EP2890389A1 (en) * | 2012-08-28 | 2015-07-08 | Novartis AG | Use of a vegf antagonist in treating ocular vascular proliferative diseases |
| US9664695B2 (en) | 2012-10-02 | 2017-05-30 | Sphingotec Gmbh | Method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction |
| EP2738180A1 (en) | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
| ES2879023T3 (es) | 2013-01-08 | 2021-11-19 | Sphingotec Gmbh | Niveles en ayunas de la hormona de crecimiento como marcador predictivo de riesgo cardiovascular |
| EP2961773B1 (en) * | 2013-02-26 | 2019-03-20 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
| JP6649246B2 (ja) * | 2013-03-14 | 2020-02-19 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | タンパク質の徐放性送達の組成物及び製造プロセス中のタンパク質の安定化方法 |
| SG11201507774YA (en) | 2013-03-20 | 2015-10-29 | Sphingotec Gmbh | Adrenomedullin to guide therapy of blood pressure decline |
| FR3004650B1 (fr) * | 2013-04-22 | 2015-05-29 | Affilogic | Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation |
| CN105209483B (zh) | 2013-05-31 | 2021-07-27 | 分子组合公司 | 与肝细胞生长因子结合的设计锚蛋白重复蛋白 |
| EP3010526A1 (en) | 2013-06-20 | 2016-04-27 | Novartis AG | Use of a vegf antagonist in treating macular edema |
| US20160137717A1 (en) | 2013-06-20 | 2016-05-19 | Gabriela Burian | Use of a vegf antagonist in treating choroidal neovascularisation |
| WO2014203181A1 (en) | 2013-06-20 | 2014-12-24 | Novartis Ag | Treatment of polypoidal choroidal vasculopathy |
| EP3019526A1 (en) | 2013-07-11 | 2016-05-18 | Novartis AG | Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients |
| RU2676303C2 (ru) | 2013-07-11 | 2018-12-27 | Новартис Аг | Использование антагониста vegf для лечения ретролентальной фиброплазии |
| DK4374873T3 (da) | 2013-07-12 | 2025-11-03 | Astellas Us Llc | Middel til brug ved behandling eller forebyggelse af oftalmologiske tilstande |
| PT3065761T (pt) * | 2013-11-05 | 2020-02-21 | Allergan Inc | Método de tratamento de condições oculares com um darpin anti-vegf |
| CN106456757A (zh) | 2014-05-12 | 2017-02-22 | 福尔密孔股份公司 | 含有vegf拮抗剂的预填充塑料注射器 |
| EP3002589A1 (en) | 2014-10-01 | 2016-04-06 | sphingotec GmbH | A method for stratifying a female subject for hormone replacement therapy |
| KR102427117B1 (ko) * | 2015-04-02 | 2022-07-29 | 몰리큘라 파트너스 아게 | 혈청 알부민에 대한 결합 특이성을 갖는 설계된 안키린 반복 도메인 |
| CN107667294B (zh) | 2015-04-24 | 2021-12-17 | 思芬构技术有限公司 | 用于预测慢性肾病发生风险的方法 |
| TWI799366B (zh) | 2015-09-15 | 2023-04-21 | 美商建南德克公司 | 胱胺酸結骨架平臺 |
| CA3005132A1 (en) | 2015-11-18 | 2017-05-26 | Sio2 Medical Products, Inc. | Coated syringe for ophthalmic formulations containing a vegf antagonist |
| EP3377100B1 (en) | 2015-11-18 | 2025-02-26 | Formycon AG | Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist |
| CN108290004A (zh) | 2015-11-18 | 2018-07-17 | 福尔密孔股份公司 | 含有vegf拮抗剂的预填充塑料注射器 |
| WO2018218013A2 (en) | 2017-05-24 | 2018-11-29 | Sio2 Medical Products, Inc. | Sterilizable pharmaceutical package for ophthalmic formulations |
| US10576128B2 (en) | 2016-01-26 | 2020-03-03 | Formycon Ag | Liquid formulation of a VEGF antagonist |
| CN115951066A (zh) | 2016-02-29 | 2023-04-11 | 麦恩泰科特有限公司 | 可用于治疗湿性年龄相关性黄斑变性的预测性标志物 |
| DE112017002105T5 (de) | 2016-04-21 | 2019-04-25 | Sphingotec Therapeutics Gmbh | Verfahren zur Bestimmung von DPP3 und therapeutische Verfahren |
| EP3474887A1 (en) | 2016-06-27 | 2019-05-01 | AiCuris Anti-infective Cures GmbH | Hcmv entry inhibitors |
| RU2019103403A (ru) | 2016-07-08 | 2020-08-10 | Сфинготек Гмбх | Адреномедуллин для оценки застоя у индивидуума с острой сердечной недостаточностью |
| BR112019001206A2 (pt) | 2016-07-20 | 2019-06-25 | Aerpio Therapeutics Inc | anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss) |
| CN109790206A (zh) | 2016-09-22 | 2019-05-21 | 分子组合公司 | 重组结合蛋白及其用途 |
| EP3309550A1 (en) | 2016-10-12 | 2018-04-18 | sphingotec GmbH | Method for the detection of apolipoprotein e4 |
| EP3339324A1 (en) | 2016-12-22 | 2018-06-27 | sphingotec GmbH | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
| JP7727371B2 (ja) | 2016-12-16 | 2025-08-21 | アドレノメト アクチェンゲゼルシャフト | うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場 |
| WO2018215580A1 (en) | 2017-05-24 | 2018-11-29 | Formycon Ag | Method for sterilizing prefilled plastic syringes containing a vegf antagonist |
| EP3630043A1 (en) | 2017-05-24 | 2020-04-08 | Formycon AG | Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist |
| EP3631459A1 (en) | 2017-05-30 | 2020-04-08 | SphingoTec GmbH | A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction |
| TW201904610A (zh) | 2017-06-14 | 2019-02-01 | 德商拜耳製藥公司 | 用於治療新生血管型青光眼之非抗體vegf拮抗劑 |
| WO2019020777A1 (en) | 2017-07-26 | 2019-01-31 | Formycon Ag | LIQUID FORMULATION OF A VEGF ANTAGONIST |
| KR20200038303A (ko) * | 2017-08-18 | 2020-04-10 | 캠브리지 엔터프라이즈 리미티드 | 모듈형 결합 단백질 |
| HRP20241795T1 (hr) | 2017-09-25 | 2025-03-14 | Adrenomed Ag | Anti-adrenomedulin (adm) – vezujući entitet za uporabu u terapiji ili prevenciji simptoma bolesti |
| WO2019077082A1 (en) | 2017-10-18 | 2019-04-25 | Adrenomed Ag | SURVEILLANCE OF THERAPY UNDER TREATMENT WITH ANTI-ADRENOMEDULIN BINDER (ADM) |
| JP7411546B2 (ja) | 2017-10-24 | 2024-01-11 | シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 初回心血管イベントの予測のためのセレノプロテインｐ |
| KR102835427B1 (ko) | 2017-10-25 | 2025-07-21 | 4틴4 파마슈티컬스 게엠베하 | 특이적 dpp3-에피토프에 대하여 지시되고 이에 결합하는 dpp3 결합제 및 산화적 스트레스와 연관되는 질환 / 급성 병태의 예방 또는 치료에서의 그의 용도 |
| CN119770645A (zh) | 2018-02-08 | 2025-04-08 | 斯弗因高泰克有限公司 | 用于诊断和/或预测痴呆症的肾上腺髓质素和抗肾上腺髓质素结合物在治疗或预防痴呆症中的应用 |
| EP3569614A1 (en) | 2018-05-18 | 2019-11-20 | Julius-Maximilians-Universität Würzburg | Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase |
| EP3586865A1 (en) | 2018-06-21 | 2020-01-01 | Charité - Universitätsmedizin Berlin | Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis |
| WO2020068653A1 (en) | 2018-09-24 | 2020-04-02 | Aerpio Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF |
| BR112021010069A2 (pt) | 2018-12-20 | 2021-11-23 | Sphingotec Gmbh | Selenoproteína p em insuficiência cardíaca |
| CN113557031A (zh) | 2018-12-21 | 2021-10-26 | 4Teen4制药有限公司 | 使用血管紧张肽受体激动剂和/或其前体的治疗的疗法指导和/或疗法监测 |
| WO2020245746A1 (en) | 2019-06-04 | 2020-12-10 | Molecular Partners Ag | Multispecific proteins |
| AU2020328194A1 (en) | 2019-08-15 | 2022-03-17 | Sphingotec Gmbh | A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction in pediatric patients |
| JP2022546061A (ja) | 2019-08-30 | 2022-11-02 | ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ショック症治療のための治療法の誘導および／または治療法の監視 |
| IL293698A (en) | 2019-12-11 | 2022-08-01 | Molecular Partners Ag | Recombinant peptide-mhc complex binding proteins, their production and use |
| EP3871689A1 (en) | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
| CN115244080A (zh) | 2020-02-27 | 2022-10-25 | 艾德里诺医药公司 | 用于治疗或预防休克的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig支架 |
| US20230193348A1 (en) | 2020-02-27 | 2023-06-22 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock |
| US20230250166A1 (en) | 2020-02-27 | 2023-08-10 | Adrenomed Ag | Anti-adrenomedullin (adm) binder for use in therapy of patients in shock |
| EP3922993A1 (en) | 2020-06-12 | 2021-12-15 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
| AU2021238591A1 (en) | 2020-03-16 | 2022-11-17 | Adrenomed Ag | Pro-Adrenomedullin or fragment thereof in patients infected with Corona virus and treatments with binder against adrenomedullin |
| BR112022017277A2 (pt) | 2020-03-16 | 2022-10-18 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 em pacientes infectados com coronavírus |
| JP2023525518A (ja) | 2020-05-06 | 2023-06-16 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 新規アンキリンリピート結合タンパク質とその用途 |
| US20240279290A1 (en) | 2020-05-14 | 2024-08-22 | Molecular Partners Ag | Multispecific proteins |
| EP4023218A1 (en) | 2020-12-02 | 2022-07-06 | S-Form Pharma | Combination therapy for patients having acute and/or persistent dyspnea |
| AU2021403833A1 (en) | 2020-12-16 | 2023-07-27 | Molecular Partners Ag | Novel slow-release prodrugs |
| CA3211368A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Novel darpin based cd123 engagers |
| US20240317852A1 (en) | 2021-03-09 | 2024-09-26 | Molecular Partners Ag | Novel darpin based cd33 engagers |
| BR112023018293A2 (pt) | 2021-03-09 | 2023-10-31 | Molecular Partners Ag | Acopladores de célula t multiespecíficos à base de darpin |
| EP4305063A1 (en) | 2021-03-09 | 2024-01-17 | Molecular Partners AG | Protease cleavable prodrugs |
| BR112023022439A2 (pt) | 2021-04-26 | 2023-12-26 | Celanese Eva Performance Polymers Llc | Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular |
| CN117529664A (zh) | 2021-06-18 | 2024-02-06 | 思芬构技术有限公司 | 用于预测脓毒症和脓毒性休克的方法 |
| US20240310387A1 (en) | 2021-06-29 | 2024-09-19 | Berysol Gmbh | Composite biomarker for the identification of selenium deficiency in a bodily fluid |
| EP4145456A1 (en) | 2021-09-06 | 2023-03-08 | Bayer AG | Prediction of a change related to a macular fluid |
| WO2023110983A1 (en) | 2021-12-14 | 2023-06-22 | Molecular Partners Ag | Designed repeat domains with dual binding specificity and their use |
| CA3254142A1 (en) | 2022-03-15 | 2023-09-21 | Adrenomed Ag | STABLE AQUEOUS FORMULATION OF AN ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR AN ANTI-ADM ANTIBODY FRAGMENT |
| AU2023315168A1 (en) | 2022-07-29 | 2025-02-13 | 4TEEN4 Pharmaceuticals GmbH | Prediction of an increase of dpp3 in a patient with septic shock |
| AU2023313376A1 (en) | 2022-07-29 | 2025-03-06 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| WO2024028278A1 (en) | 2022-08-01 | 2024-02-08 | Molecular Partners Ag | Charge modified designed repeat domains and their use |
| WO2024038307A1 (en) | 2022-08-19 | 2024-02-22 | Novartis Ag | Dosing regimens for sars-cov-2 binding molecules |
| WO2024059686A2 (en) * | 2022-09-15 | 2024-03-21 | The Regents Of The University Of California | Darpin backbones and rigidified electron microscopy imaging scaffolds |
| JP2025541138A (ja) | 2022-12-15 | 2025-12-18 | ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 重篤な患者における肺機能の改善のためのｄｐｐ３阻害剤 |
| EP4673159A1 (en) | 2023-02-27 | 2026-01-07 | Molecular Partners AG | Darpins for use in reducing renal accumulation of drugs |
| JP2026510789A (ja) | 2023-03-17 | 2026-04-10 | ペーアーエム セラノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | ペプチジルグリシンα－アミド化モノオキシゲナーゼ（ＰＡＭ）の測定法及び診断目的のためのその使用 |
| EP4687942A1 (en) | 2023-03-29 | 2026-02-11 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 inhibitor for myocardial protection and prevention of myocardial injury in critically ill patients with blood pressure decline |
| CN121889677A (zh) | 2023-09-25 | 2026-04-17 | 思芬构技术有限公司 | 用于肾移植患者中移植物功能降低的早期诊断、早期预测、监测或严重程度预测的方法 |
| WO2025146491A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent |
| WO2025229075A1 (en) | 2024-05-03 | 2025-11-06 | Sphingotec Gmbh | A method for the specific determination of proenkephalin fragment 119-159 |
| WO2025248139A1 (en) | 2024-05-31 | 2025-12-04 | 4TEEN4 Pharmaceuticals GmbH | Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof |
| EP4675277A1 (en) | 2024-07-05 | 2026-01-07 | Predemtec AG | A method for diagnosing alzheimer´s disease or determining the risk of suffering from alzheimer´s disease |
| WO2026046968A1 (en) | 2024-08-26 | 2026-03-05 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 binders for the treatment of endothelial dysfunction |
| WO2026046978A1 (en) | 2024-08-26 | 2026-03-05 | Pam Theragnostics Gmbh | Anti-adm antibodies, anti-adm antibody fragment or anti-adm non-ig scaffold for therapy or prevention of immune effector cell therapy side effects |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| US5348867A (en) | 1991-11-15 | 1994-09-20 | George Georgiou | Expression of proteins on bacterial surface |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
| PT971959E (pt) | 1997-04-07 | 2006-05-31 | Genentech Inc | Anticorpos humanizados e metodos para formar anticorpos humanizados |
| KR100816621B1 (ko) | 1997-04-07 | 2008-03-24 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체 |
| EP0975748B1 (en) | 1997-04-23 | 2006-03-29 | Universität Zürich | Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules |
| NZ511699A (en) | 1998-12-02 | 2003-02-28 | Phylos Inc | DNA-protein fusions and uses thereof |
| US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| CN101433715B (zh) | 1999-06-08 | 2013-04-17 | 里珍纳龙药品有限公司 | 具有改善的药物动力学特性的修饰嵌合多肽 |
| EP1332209B1 (en) * | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| RU2299208C2 (ru) * | 2001-05-08 | 2007-05-20 | Шеринг Акциенгезельшафт | Антраниламидпиридинамиды избирательного действия в качестве ингибиторов vegfr-2 и vegfr-3 |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| US7772188B2 (en) * | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| EP1711196A4 (en) * | 2003-12-05 | 2011-09-14 | Bristol Myers Squibb Co | INHIBITORS OF TYPE-2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS |
| JP2008519590A (ja) * | 2004-11-12 | 2008-06-12 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 組換えニューカッスル病ウィルス |
| ES2633574T3 (es) * | 2005-03-25 | 2017-09-22 | Regeneron Pharmaceuticals, Inc. | Formulaciones de antagonistas de VEGF |
| BRPI0613593A2 (pt) | 2005-07-08 | 2011-01-18 | Univ Zuerich | método de teste "phage display" filamentoso, vetor de fago ou de fagomìdeo e biblioteca de vetores de fago ou fagomìdeo |
| MX2009005466A (es) | 2006-11-22 | 2009-08-17 | Adnexus A Bristol Myers Sqibb | Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas, incluyendo receptor de factor de crecimiento tipo insulina-i. |
| BRPI0806414A2 (pt) * | 2007-02-01 | 2011-09-06 | Genentech Inc | método para tratamento de tumor |
| EP2111228B1 (en) | 2007-02-02 | 2011-07-20 | Bristol-Myers Squibb Company | 10Fn3 domain for use in treating diseases associated with inappropriate angiogenesis |
-
2009
- 2009-11-03 BR BRPI0921469-0A patent/BRPI0921469B1/pt active IP Right Grant
- 2009-11-03 RU RU2011122201/10A patent/RU2550258C2/ru active
- 2009-11-03 MX MX2011004649A patent/MX2011004649A/es unknown
- 2009-11-03 MX MX2015010520A patent/MX359570B/es unknown
- 2009-11-03 ES ES09756279T patent/ES2836948T3/es active Active
- 2009-11-03 US US13/126,821 patent/US8901076B2/en active Active
- 2009-11-03 AU AU2009319204A patent/AU2009319204B2/en active Active
- 2009-11-03 DK DK09756279.7T patent/DK2358746T3/da active
- 2009-11-03 RU RU2015108838A patent/RU2650765C1/ru active
- 2009-11-03 JP JP2011533752A patent/JP5954990B2/ja active Active
- 2009-11-03 CA CA2742241A patent/CA2742241C/en active Active
- 2009-11-03 EP EP20196328.7A patent/EP3785735A1/en not_active Withdrawn
- 2009-11-03 KR KR1020117009012A patent/KR101698362B1/ko active Active
- 2009-11-03 EP EP09756279.7A patent/EP2358746B1/en active Active
- 2009-11-03 CN CN201710092752.9A patent/CN107011425B/zh active Active
- 2009-11-03 WO PCT/EP2009/064483 patent/WO2010060748A1/en not_active Ceased
- 2009-11-03 CN CN2009801536047A patent/CN102272148A/zh active Pending
- 2009-11-03 NZ NZ592591A patent/NZ592591A/en unknown
-
2011
- 2011-04-28 IL IL212589A patent/IL212589A/en active IP Right Grant
-
2014
- 2014-10-28 US US14/525,553 patent/US20150344539A1/en not_active Abandoned
-
2015
- 2015-03-17 JP JP2015053249A patent/JP6329503B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK2358746T3 (da) | 2020-12-21 |
| CA2742241A1 (en) | 2010-06-03 |
| CN107011425B (zh) | 2021-01-01 |
| MX359570B (es) | 2018-10-01 |
| JP5954990B2 (ja) | 2016-07-20 |
| JP2015133978A (ja) | 2015-07-27 |
| CN102272148A (zh) | 2011-12-07 |
| JP2012507271A (ja) | 2012-03-29 |
| RU2650765C1 (ru) | 2018-04-17 |
| AU2009319204A1 (en) | 2010-06-03 |
| AU2009319204B2 (en) | 2014-11-13 |
| KR101698362B1 (ko) | 2017-01-20 |
| KR20110082528A (ko) | 2011-07-19 |
| RU2011122201A (ru) | 2012-12-10 |
| WO2010060748A1 (en) | 2010-06-03 |
| BRPI0921469A2 (pt) | 2016-01-12 |
| EP2358746B1 (en) | 2020-09-16 |
| ES2836948T3 (es) | 2021-06-28 |
| US20150344539A1 (en) | 2015-12-03 |
| CN107011425A (zh) | 2017-08-04 |
| EP3785735A1 (en) | 2021-03-03 |
| EP2358746A1 (en) | 2011-08-24 |
| RU2550258C2 (ru) | 2015-05-10 |
| NZ592591A (en) | 2012-04-27 |
| IL212589A0 (en) | 2011-07-31 |
| MX2011004649A (es) | 2011-05-30 |
| US8901076B2 (en) | 2014-12-02 |
| CA2742241C (en) | 2019-12-10 |
| BRPI0921469B1 (pt) | 2022-01-18 |
| US20110207668A1 (en) | 2011-08-25 |
| JP6329503B2 (ja) | 2018-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL212589A0 (en) | Binding proteins inhibiting the vegf-a receptor interaction | |
| IL222749A0 (en) | Modified binding proteins inhibiting the vegf-a receptor interaction | |
| GB2461546B (en) | Antigen binding polypeptides | |
| IL243784A0 (en) | Human cgrp receptor binding proteins | |
| GB2449354B (en) | Binding protein | |
| ZA201104397B (en) | Myostatin binding proteins | |
| IL206188A0 (en) | Antigen binding proteins | |
| PL3118220T3 (pl) | Białko | |
| IL210264A0 (en) | Tnf - ?? antagonist multi - target binding proteins | |
| ZA201000283B (en) | Reinigung pegylierter polypeptide | |
| IL236236A (en) | Antibodies to the fam26f polypeptide | |
| EP2370008A4 (en) | RESTRUCTURING THE VERTEBRAL COLUMN | |
| ZA201008335B (en) | Interleukin-21 receptor binding proteins | |
| GB0816976D0 (en) | Protein | |
| GB0816702D0 (en) | Complement proteins | |
| GB0719231D0 (en) | Protein | |
| GB0720563D0 (en) | Protein | |
| GB0818627D0 (en) | Protein | |
| IL210002A0 (en) | Antigen binding polypeptides | |
| GB0804680D0 (en) | Binding polypeptides | |
| GB0714346D0 (en) | binding peptides | |
| GB0704842D0 (en) | Binding polypeptides | |
| GB0719236D0 (en) | Protein | |
| GB0713302D0 (en) | Protein | |
| IL206541A0 (en) | Novel protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |